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prevent HIV infection in heterosexual populations:
implications for product development and prevention
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ABSTRACT
Objectives To compare the potential impact of rectal
(RMB), vaginal (VMB) and bi-compartment (RVMB)
(applied vaginally and protective during vaginal and anal
intercourse) microbicides to prevent HIV in various
heterosexual populations. To understand when a RMB is
as useful than a VMB for women practicing anal
intercourse (AI).
Methods Mathematical model was used to assess the
population-level impact (cumulative fraction of new HIV
infections prevented (CFP)) of the three different
microbicides in various intervention scenarios and
prevalence settings. We derived the break-even RMB
efficacy required to reduce a female’s cumulative risk of
HIV infection by the same amount than a VMB.
Results Under optimistic coverage (fast roll-out, 100%
uptake), a 50% efficacious VMB used in 75% of sex acts
in population without AI may prevent w33% (27, 42%)
new total (men and women combined) HIV infections
over 25 years. The 25-year CFP reduces to w25% (20,
32%) and 17% (13, 23%) if uptake decreases to 75% and
50%, respectively. Similar loss of impact (by 25%e50%)
is observed if the same VMB is introduced in populations
with 5%e10% AI and for RRRAI¼4e20. A RMB is as
useful as a VMB (ie, break-even) in populations with 5%
AI if RRRAI¼20 and in populations with 15%e20% AI if
RRRAI¼4, independently of adherence as long as it is the
same with both products. The 10-year CFP with a RVMB
is twofold larger than for a VMB or RMB when AI¼10%
and RRRAI¼10.
Conclusions Even low AI frequency can compromise
the impact of VMB interventions. RMB and RVMB will
be important prevention tools for heterosexual
populations.
INTRODUCTION
Research on vaginal microbicide (VMB) to prevent
HIV infection is important because it is a biomed-
ical intervention speciﬁcally designed to protect
women.1 Until July 2010, none of the ﬁrst genera-
tion of microbicide candidates (ie, with non-speciﬁc
activity against HIV) tested in large clinical trials
had shown to protect against HIV.1e4 One clinical
trial (CAPRISA-004) has demonstrated the effec-
tiveness of a topical antiretroviral-based vaginal
microbicide (ARV-VMB), tenofovir 1% gel, against
HIV acquisition among women in South Africa5 6
(table 1). This was the ﬁrst topical ARV-VMB with
speciﬁc activity against HIV-1 (suppress viral
replication) to be tested. This positive result needs
to be conﬁrmed in other trials before it can be
licensed and used as a public health prevention
tool. Many additional products designed to
protect during vaginal and anal intercourse are
currently at different stages of development and
testing.4 7e9
The role of anal intercourse (AI) in the overall
heterosexual HIVepidemic remains unclear. AI may
be an important risk factor because the risk of HIV
infection during unprotected receptive AI is much
larger than during vaginal intercourse (VI)10e14 and
because the fraction of heterosexuals who engaged
in AI at least once in their lifetime is substantial in
different risk populations, countries and time
periods (online Supplement table S1).11 15e17 AI
may also be signiﬁcantly under-reported. For
example, in one study, 3.5% of married men in
Cotonou reported ever engaging in AI with
a woman in face-to-face interviews compared with
17.5% in a pooling booth survey, a method designed
to reduce social desirability bias.18
Theoretical studies have also raised the concern
that the practice of AI by trial participants may have
reduced the effectiveness of VMB in large clinical
trials.19 20 VMB use is currently limited to VI due to
insufﬁcient safety data on rectal use.19e21 However,
data in animal studies indicate that tenofovir gel can
protect during rectal challenges.22 23 In theory, it is
biologically possible for a vaginally applied ARV-
VMB gel to diffuse from the vaginal to the rectal
linings and to protect during AI.5 24 Thus, the
development of a rectal microbicide (RMB) or bi-
compartmental microbicide that protect during
vaginal and anal intercourse (RVMB) may eventu-
ally be possible and a useful HIV prevention tool for
heterosexual populations. Previous mathematical
modelling studies have assessed the potential impact
of VMB and RMB in heterosexual and homosexual
populations, respectively.9 25e30 However, none have
investigated the potential impact of RMB or RVMB
in heterosexual population.31
Our study aims to ﬁll this gap by comparing the
long-term population-level impact of VMB, RMB
and RVMB in different heterosexual populations,
HIV prevalence settings and intervention scenarios.
First, we use a transmission dynamics model to
assess the VMB intervention impact in populations
without AI under various coverage scenarios. Then,
we compare the ‘loss of VMB impact’ due to AI in
populations with AI and due to reduced coverage in
populations without AI. Third, we assess the
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relative and incremental population-level impact of RMB/RVMB
compared with VMB under different efﬁcacy, adherence and anal
sex assumptions. Finally, we derive the ‘break-even RMB efﬁ-
cacy ’ to quantify the usefulness of a RMB, compared with




To assess the microbicide population-level impact, we expanded
a previously published deterministic model of heterosexually
transmitted HIV infection and vaginal microbicide use to include
AI, condom use and adherence to a vaginal or rectal micro-
bicide.26 The model assumes random mixing between suscep-
tible and infectious individuals and divides the population into
three major classes: men, women not using and using micro-
bicides, which are further stratiﬁed in susceptible, HIV infected
and AIDS states (online Appendix A). Men and women who
become sexually active join the community at constant rates,
which are selected to balance the departure rate in a non-
infected population (ie, open but stable population). The gender-
speciﬁc rates of HIV infection, that is, the forces of infection, for
the different classes depend on the annual rate of new partner
acquisition, the number of sex acts per partnership, the fraction
of all sex acts, which are anal (a) and vaginal (1a), and the HIV
transmission probability per anal or vaginal sex act, the fraction
of sex acts protected by condoms (c) or by microbicide during
vaginal (gVMB) or/and anal (gRMB) intercourse, and the HIV
prevalence among the partners of opposite sex.
Microbicide intervention
Theoretically, depending on the product, a microbicide can
protect directly against HIV (HIV efﬁcacy) or indirectly by
protecting against cofactor sexually transmitted infection (STI)
(STI efﬁcacy) during AI or VI.32 Microbicide use can reduce
susceptibility (acquisition) to HIV infection of uninfected
women or reduce the infectiousness (transmission) of infected
women to their male partners.3 5 In the CAPRISA-004 trial, the
vaginal use of tenofovir 1% gel signiﬁcantly reduced HIV inci-
dence among women but did not reduce the viral load of VMB
users who seroconverted. No drug resistance due to VMB use
was observed during the trial.5 Although ARV-based micro-
bicides are not necessarily expected to protect against cofactor
STI, tenofovir gel signiﬁcantly reduced herpes simplex virus-2
incidence in the CAPRISA-004 trial.5 Data from the CAPRISA-
004 trial suggest that vaginally applied tenofovir gel may have
diffused from the women’s vaginal linings to the rectal linings
(thereby explaining the increase in mild diarrhoea seen in
CAPRISA-004) opening the interesting, yet unproven, possibility
that the gel could also protect during AI.24 It remains unknown
if such microbicide would be equally protective during AI than
VI, although animal studies suggest that a MB gel could be
equally effective during AI and VI.22 23
Based on this information, we modelled three microbicides,
which are assumed to reduce the women risk of HIVacquisition
during receptive VI only (VMB), during RAI only (RMB) or
during both (RVMB) with an efﬁcacy of EVMB, ERMB and ERVMB,
respectively. The risks associated with drug resistance and
condom substitution were not considered. We modelled the
increase in coverage by assuming that the microbicide is
immediately adopted by a fraction k1 (speed of roll-out) of
women in the population and by an additional fraction
k (uptake) of women who newly enter the sexually active
population annually. The parameter k determines the maximum
long-term achievable coverage, whereas k1 inﬂuences how fast it
is achieved. We deﬁned a fast (k1¼k) and a slow roll-out
(k1¼k/2). The model is described fully in online Appendix A.
Parameter assumptions and simulations
We deﬁned ranges of values for the behavioural and biological
parameters that are representative of different risk populations in
Southern Africa and produced epidemics with HIV equilibrium
prevalence between >0% and 35% (table 2A,B).18 35 38 39 42 43
The gender-speciﬁc HIV transmission probability estimates per
vaginal and anal act and the relative increase in HIV acquisition
risk during RAI (RRRAI¼4 to 20) (online Appendix C) are based
on meta-analyses of observational studies.11e14 The limited data
on HIV risk per insertive anal intercourse (IAI) indicate a lower
risk than for RAI.10 11 14 We conservatively assumed a twofold
increase in HIV risk during IAI (RRIAI) compared with insertive
VI. Fewer studies report data on AI frequency than on the frac-
tion of individuals who ever practiced AI.12 Overall, 6%e10% of
all unprotected sex acts reported by study participants (town-
ships, STI clinics) in Cape Town were AI.12 17 Similarly 10% of all
unprotected sex acts reported by female sex workers (FSWs) in
Durban were AI.36 In previous multicentre VMB trials, 2%e4%
low-risk women reported at least one episode of AI in the month
prior to enrolment.19 20 36 37 In comparison, between 1.2% and
6.3% of adults in France, Brazil, USA and Australia reported AI at
their last sex (online Supplement table S1).44e48 Thus, we
explored scenarios with AI frequency of 0%, 2%, 5%, 10%, 15%
and 20%. We also allow for a signiﬁcant variation in the
community rate of condom use, annual frequency of sex acts,
annual number of sex partners and condom efﬁcacy (table 2A).
In the CAPRISA-004 trial, the true efﬁcacy of tenofovir gel
against HIV remains uncertain. It could be over or under-
estimated since the estimated overall effectiveness (a reﬂection
of the true efﬁcacy and adherence) of tenofovir against HIV was
39%, after 30 months, under imperfect adherence (72% overall),
and because tenofovir gel also protected against herpes simplex
virus-2 acquisition, which is a cofactor of HIV49 (table 1). Using
this information, we predominantly explored efﬁcacy around
30%, 50%, 75% and adherence around 50% and 75% but also
varied them over a wider range (table 2C). We assumed that the
RVMB is equally effective during AI and VI. We explored an







Intention to treat 39% (6 to 60) 72% 54.2%
Per protocol 41% (7 to 63)
Adjusted 37% (6 to 58)
Subanalysis
Rural 43% (5 to 67) NA
Urban 26% (59 to 67) NA
High gel adherence 54% (4 to 80) >80% <67.5%
Medium gel adherence 38% (67 to 77) 50%e80% 47.5%e76.0%
Low gel adherence 28% (40 to 64) <50% >56%
At 12-month follow-up 50% NA
At 24-month follow-up 40% NA
*The observed effectiveness in trials reflects the combination between the real
(unmeasured) efficacy of the microbicide and the adherence to the product. Based on the
information available, we can crudely estimate the ‘true’ efficacy as the observed
effectiveness divided by the observed adherence. The overall adherence during the trial was
72%, which means that the true efficacy could be around 54%, which is similar to the trial
effectiveness estimate among high adherers.
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optimistic (k1¼k¼100%) and ﬁve alternative coverage scenarios
with lower uptake (50%, 75%), with slow and fast roll-out
(table 2D). The optimistic scenario serves as the reference when
comparing the loss of impact due to AI and reduced coverage.
Monte Carlo sampling was used to randomly select different
pre-intervention parameter sets from their predeﬁned uniform
ranges (table 2A). The pre-intervention parameters were ﬁltered
to identify 1000 parameter sets that met predeﬁned target
criteria of (1) basic reproductive number R0>1 in absence
of intervention and (2) equilibrium HIV prevalence below 35%
(table 2B). The intervention is introduced in the different
mature simulated HIV epidemics. The population-level effec-
tiveness of the intervention is measured as the cumulative
fraction of new HIV infections prevented over the period [0,T]
(CFP) following the start of the intervention. We report the
median and the 90% uncertainty interval (90% UI), derived from
the various parameter sets, which reﬂects the inﬂuence of the
epidemiological conditions on the impact estimates.
Break-even efficacy ðEbreak-evenRMB Þ
The usefulness of RMB compared with VMB for women prac-
ticing AI was assessed by the break-even RMB efﬁcacy
ðEbreakevenRMB Þ (equation 1) which was derived from the formula of
the cumulative risk of HIV infection over ﬁxed time period, for
women using a VMB or RMB during sex (CRpw; online Appendix
B equations B.1eB.2), and is embedded in the expressions for the
force of infection of the deterministic model (online Appendix
B). Equation 1 determines the minimum RMB efﬁcacy required
to reduce a woman’s risk of HIV infection by the same amount
than a VMB assuming that 100% of sex acts are with a HIV-
positive partner, the same adherence with both products, no
condom substitution and no reduction in HIV infectiousness
due to microbicides use (online Appendix B). Under these
assumptions, the equivalence between a RMB and VMB only
depends on the relative efﬁcacy of the RMB (ERMB) and VMB
(EVMB), the frequency of AI (a) and the increase in HIV risk
during RAI (RRRAI) compared with the risk during receptive VI




A. Parameters sampled pre-intervention
bm HIV acquisition risk for men per unprotected vaginal act 0.0021e0.0068* 13
bw HIV acquisition risk for women per unprotected vaginal act 0.0019e0.0046* 13
1/m Average time to remain sexually active 30e40 years
d HIV-related mortality rates 1/12e1/7 33 34
nw, nm Average number of sexual acts per year for women and men 50e150 17 28 35e37
r Average number of sexual partners per year for women
and men
0.5e2 16 18 26 35 38 39
c Rate of condom use in general population; fraction of sex acts
when a condom is used
0%e60% 17 35 36 40
ac Condom efficacy per act 0.80e0.95 41
RRRAI Relative HIV acquisition risk per receptive anal act compared
with receptive vaginal act
2, 4, 10, 20 10e14
RRIAI Relative HIV acquisition risk per insertive anal act compared
with insertive vaginal act
2 10 11 14
a Frequency of anal intercourse, fraction of all (unprotected)
sex acts which are anal intercourse
0%, 2%, 5%, 10% 15%, 20% Online Supplement table S1
B. Characteristics of epidemics simulated
R0 Basic reproductive rate 1.00e1.65 Simulations
y* Overall HIV equilibrium prevalence >0%e35% Simulations5 17 42 43
C. Intervention parameters
k Uptake: fraction of new sexually active women entering the
population using MB
50%, 75%, 100% Assumed
k1 Speed of roll-out: initial proportion of women in the population
using MB
Fast k1¼k; slow k1¼k/2
gRMB, gVMB Adherence: fraction of sex acts protected by microbicide when
using or not using condoms
50%, 75% and (0%e30%)y, (60%e90%)y Table 15
EVMB VMB efficacy: reduction in susceptibility per vaginal act 30%, 50%, 75% and between 15% and 90% Table 1
5
ERMB RMB efficacy: reduction in susceptibility per anal act 30%, 50%, 75% and between 15% and 90% Assumed
D. Intervention scenarios modelled
Optimistic coverage (for VMB, RMB, RVMB)
Uptake and roll-out k1¼k¼100%
Efficacy EVMB, ERMB, ERVMB varied
Adherence gRMB, gVMB¼varied
Anal sex a and RRRAI varied
Alternative more realistic coverage (for VMB only)





*80% CI of the pooled estimate.13
yRanges uniformly sampled.
subscript w, women; subscript m, men; superscript p, microbicide user; RAI, receptive anal intercourse; IAI, insertive anal intercourse.
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(bw); it is independent of the men increased in HIV risk during





















Population-level impact of VMB by coverage level
Figure 1A shows the fraction of female MB user (coverage) under
different uptake and roll-out assumptions. With 50% uptake and
slow roll-out, 25% and 40% of women use the MB after 1 and
25 years, respectively (low coverage). With 100% uptake and fast
roll-out, all women immediately use MB (optimistic coverage).
Figure 1BeD shows the cumulative fraction of new HIV infec-
tions prevented (CFP) over time following the MB introduction.
Under optimistic coverage, a 50% efﬁcacious VMB, used in 75%
of sex acts in populations without AI, is expected to prevent
35% (90% UI: 33e36%) and <3% new HIV infections in the ﬁrst
year among women and men, respectively (ﬁgure 1B). However,
the difference between men and women reduces over time solely
due to ‘herd effects’ (ie, men are indirectly protected by female
users) since the microbicide does not reduce the infectiousness of
HIV-positive females. As expected, the VMB impact is reduced if
coverage decreases (ﬁgure 1C). With fast roll-out, the 25-year
total (men and women combined) CFP reduces from 33% (90%
UI: 27e42) to 25% (90% UI: 20e32) and to 17% (90% UI:
13e23), respectively, when uptake decreases from 100% to 75%
and to 50% (ﬁgure 1C). Over 10 years, only 8% (90% UI: 7e9%)
total HIV infections are prevented with low coverage (slow roll-
out, 50% uptake).
Loss in VMB population-level impact due to AI
Under optimistic coverage, the median total 25-year CFP reduces
from 33% in populations without AI to 27%, 21% and 15% in
populations with 5% AI if RRRAI¼4, 10 and 20, respectively
(ﬁgure 1D). Thus, levels of only 5% AI could produce the same
loss in VMB impact than a 25%e50% reduction in uptake
(ﬁgure 1C).
Relative population-level impact of RMB and VMB
Figure 2AeD compares the total 10-year CFP of a VMB and
RMB for different efﬁcacy, adherence, AI frequency and RRRAI,
under optimistic coverage. VMB impact reduces rapidly as AI
frequency increases independently of the efﬁcacy or adherence
assumed. When AI frequency increases from 0% to 5%, 0% to
10% and 0% to 20%, the median 10-year CFP of VMB is
reduced by w18%, w32% and w52% if RRRAI¼4 or w36%,
w55% and w75% if RRRAI¼10, respectively. To produce the
same impact in populations practicing AI as in populations not
practicing AI, the VMB adherence or efﬁcacy needs to be
considerably higher. To prevent a median of 10% new infections
over 10 years with a 30% efﬁcacious, VMB requires 50%
adherence in absence of AI compared with 75% adherence in
populations with 5% AI if RRRAI¼10 (ﬁgure 2D) or 10% AI if
RRRAI¼4 (ﬁgure 2C). Alternatively, if RRRAI¼10, a 75% or
50% efﬁcacious VMB used in populations with 5% AI is not
more effective than a 50% or 30% efﬁcacious VMB in absence
of AI, independently of the adherence level. Finally, RMB
impact increases sharply as AI frequency increases. For example,
a RMB which has the same efﬁcacy and adherence level as
Figure 1 (A) Fraction of women using
MB over time (coverage) following the
intervention start for different uptake
and roll-out (fast, slow) assumptions;
cumulative fraction of new HIV
infections prevented (CFP) over time
among men and women not practicing
anal intercourse (AI) (AI¼0%) and under
optimistic coverage (100% uptake, fast
roll-out) (B) and among the total
population (men and women combined)
(CeD) following the introduction of
a 50% efficacious VMB (EVMB¼50%)
used in 75% of sex acts (adherence
level (adh)¼75%). In (C), nobody
practice AI (AI¼0%), uptake and roll-out
are varied; in (D), AI¼5%, RRRAI are
varied and assumes optimistic
coverage. The box plots (median, 5th,
25th, 75th, 95th percentiles) reflect the
variation in impact estimates due to the
1000 different parameters sets (ie,
epidemiological conditions) explored.
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a VMB is expected to prevent the same fraction of infections
in populations with 20% AI if RRRAI¼4 (ﬁgure 2A,C) or
in populations with approximately 10% AI if RRRAI¼10
(ﬁgure 2B,D).
Incremental benefit of bi-compartmental RVMB
Figure 3 shows the incremental beneﬁt of a bi-compartmental
RVMB, which is equally efﬁcacious during VI and AI compared
with a VMB only or RMB only. Under optimistic coverage and
60%e90% adherence, the 10-year CFP with a 45%e60% efﬁca-
cious RVMB is 27% (90% UI: 20e35%). The impact of the
RVMB is insensitive to the frequency of AI or RRRAI. However,
the incremental beneﬁt of a RVMB compared with a single VMB
(RMB) increases (decreases) with the frequency of AI or RRRAI.
For example, the 10-year CFP of a bi-compartmental RVMB is
1.2- orw6-fold larger than a single VMB or a RMB, respectively,
in populations with 5% AI if RRRAI¼4 (ﬁgure 3A) but it is
twofold larger than for single VMB or RMB in population with
10% AI if RRRAI¼10 (ﬁgure 3D). However, even under opti-
mistic coverage, a 45%e60% efﬁcacious RVMB prevent <10%
total new infections over 10 years if adherence is below 30%,
independently of AI frequency and RRRAI (online Supplement
ﬁgure S2).
Usefulness of RMB to protect women practicing AI
Figure 4 shows the minimum, or break-even, efﬁcacy ðEbreakevenRMB Þ
required for a RMB to reduce female HIV risk by the same
amount as a 40% efﬁcacious VMB, in function of the AI
frequency and RRRAI, if both products are used as frequently.
Understandably, if half of the sex acts are AI, the break-even
efﬁcacy is 40% even if RRRAI¼1. When the AI frequency is
between 5% and 20%, the break-even efﬁcacy strongly depends
on RRRAI. For example, 40% efﬁcacious RMB and VMB are
equally useful in populations with 5% AI if RRRAI¼18, with
10% AI if RRRAI¼8 or with a 20% AI frequency if RRRAI¼4. In
many instances (eg, a¼7.5% if RRRAI>16, a¼10% if RRRAI>12),
a 20%e30% efﬁcacious RMB can even be more useful than
a 40% efﬁcacious VMB. However, with <2.5% AI, a RMB is
unlikely to be as useful as a 40% efﬁcacious VMB, unless the
Figure 2 The total (men and women combined) cumulative fraction of
new infections prevented by a VMB and RMB over 10 years (10-year CFP)
after the MB introduction assuming same adherence to both products,
optimistic coverage, and various anal intercourse (AI) frequency and MB
efficacy. In (A), adherence level (adh)¼50% and RRRAI¼4; in (B),
adh¼50% and RRRAI¼10; in (C), adh¼75% and RRRAI¼4; in (D), adh¼75%
and RRRAI¼10. Each box plot represents the median (5th, 25th, 75th, 95th
percentiles) from 1000 simulations for each of the 36 scenarios per panel.
Figure 3 The 10-year total (men and
women combined) cumulative fraction
of new infections prevented by a VMB
only, RMB only and RVMB
(ERMB¼EVMB) after the introduction of
the MB intervention of various efficacy
(from 15% to 90%) assuming 60%e90%
adherence to both products and
optimistic coverage. In (A), 5% anal
intercourse (AI) and RRRAI¼4; in (B),
5% AI and RRRAI¼10; in (C), 10% AI and
RRRAI¼4; in (D), 10% AI and RRRAI¼10.
The box plots (median, 5th, 25th, 75th,
95th percentiles) are derived from
10 000 different parameters sets.
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¼ 1:8) more efﬁ-
cacious than the VMB (ie, EbreakevenRMB ¼ 72%) and RRRAI¼20.
These results are independent of the adherence assumed as long
as it is the same for both products. From equation 1, we can
show that, for a ﬁxed RRRAI and AI frequency, the break-even is
approximately independent of EVMB. Of note, the break-even
conditions (in term of AI frequency and RRRAI) are similar to
those observed for the population-level impact derived with the
dynamical model (ﬁgure 2) because of the proportionate mixing
assumption.
DISCUSSION
Our study on the relative impact of VMB, RMB and RVMB in
heterosexual populations provides valuable information for
product developers and policy makers.
First, we estimated that in populations not practicing AI,
a 50% efﬁcacious VMB may prevent a median ofw8% (90% UI:
7e9%) total (men and women) new HIV infections over
10 years with slow roll-out and 50% uptake (coverage increasing
from 25% to 35% after 10 years) compared withw16% (90% UI:
15e17%) with 100% uptake (ﬁgure 1C). We showed that the
inﬂuence of AI frequency is as important as coverage when
assessing the population-level impact of MB interventions since
a 5%e10% AI frequency could produce a similar loss in VMB
impact as a 25%e50% reduction in coverage if RRRAI¼4e20
(ﬁgure 1C,D).
Our results are useful to determine the desirable characteris-
tics that a MB must have to be of public health use in different
populations (ie, “How good is good enough”).31 To produce the
same 10-year CFP as a 50% efﬁcacious VMB in populations
without AI, under the same conditions of use, a VMB would
have to be 75% efﬁcacious in populations with 5% AI if
RRRAI¼10 (ﬁgure 2). A RVMB may be approximately twofold
more effective than a RMB or VMB in populations with >10%
AI and RRRAI¼10 (ﬁgure 3). Thus, a dual protection seems
a desirable MB characteristic.
We showed that AI can reduce the impact of VMB to the
extent that RMB can become as useful as VMB, for a wide range
of plausible AI and RRRAI, despite being used in much fewer sex
acts overall than a VMB (ﬁgures 2 and 4). Our break-even efﬁ-
cacy analysis suggested that, in many instances when both
products are used as frequently, even a slightly less efﬁcacious
RMB could be more useful than a VMB, especially in popula-
tions with >15%e20% AI. Below this, the relative (incremental)
beneﬁt of RMB (RVMB) compared with VMB strongly depends
on the RRRAI assumed.
In this analysis, we explored various VMB coverage and
adherence scenarios. Although the optimistic coverage will likely
overestimate the potential impact of a microbicide intervention,
especially on the short to medium term,50e52 they are unlikely
to inﬂuence the relative comparison between RMB, VMB and
RVMB. The optimistic scenario helps to appreciate the
maximum impact that a MB with ﬁxed efﬁcacy can have and to
determine the very minimum MB efﬁcacy required to be useful.
For example, a 30%e45% RVMB would have a modest impact if
adherence was <30% even under optimistic coverage (online
Supplement ﬁgure S2). Adherence is an important determinant
of the potential success of microbicide interventions. Although
overall gel adherence in the CAPRISA-004 trial was high at 72%,
this may overestimate the potential achievable adherence level
in populations in real-life setting.5 How often a microbicide will
be used will depend, among others things, on the delivery
system (eg, coital or daily gel or slow release ring), individual
preferences, availability, acceptability and cost of the
product.53e55
We did not investigate the potential impact of condom
substitution, where women switch from more effective condom
to a potentially less effective microbicide and assumed the same
adherence with RMB and VMB. Condom substitution can
worsen the HIV epidemic if it is frequent, especially with
product of poor to moderate efﬁcacy, or if initial condom use is
high prior to the VMB introduction.27 28 31 56 Given that
condom use is sometimes less frequently reported during AI
than VI, a RMB may have the additional advantage of mini-
mising the risk of condom substitution especially in populations
with high rates of condom use during VI (eg, FSWs with
commercial clients).57 58 On the other hand, a coital topical
RMB may be used less frequently than a VMB because AI may
not always be planned. However, adherence could be improved
with slow release RMB and especially with bi-compartmental
RVMB since they would only need to be applied vaginally to
protect during AI.53 In the CAPRISA-004 trial, the gel needed to
be applied 12 h before and after each sex act, which may have
protected during multiple sex acts during this 24 h window
period.5 The measurable effectiveness of tenofovir in the
CAPRISA-004 trial may also be due to the fact that very few
women reported AI or perhaps (although premature to
conclude) because the gel also protected during AI, despite being
vaginally applied.
The precision of our model predictions is limited because
available estimates of HIV risk during URAI and UIAI are
imprecise and because many studies report the proportion of
individuals who ever engaged in AI over ﬁxed time periods but
do not report the frequency of unprotected AI and VI, which is
required to more precisely assess the future role of RMB and
VMB in speciﬁc populations.12 Ideally information on AI should
Figure 4 (A) Contour plot representing the minimum efficacy
ðEbreakevenRMB Þ required for a RMB to be as useful as a 40% efficacious
VMB for a woman practicing anal intercourse (AI) with a HIV-positive
partner in function of the AI frequency (a) and increased HIV risk during
RAI (RRRAI). The results are based on equation 1, which assumes same
adherence with both products and bw¼0.003. The region above the
EbreakevenRMB ¼40% efficacy boundary indicates the conditions when the
RMB can be less efficacious than the VMB and still be as usefuldwhich
also means that the 40% efficacious RMB is more useful than the 40%
efficacious VMB. The region below the 40% boundary indicates when the
RMB needs to be more efficacious than the VMB to be as useful.
Sex Transm Infect 2011;87:646e653. doi:10.1136/sextrans-2011-050184 651
AIDS 2031
 group.bmj.com on November 23, 2011 - Published by sti.bmj.comDownloaded from 
be collected using interviewing techniques to reduce social
desirability bias.18 38 In our model, we have assumed random
mixing between those who practice and do not practice AI.
Data on mixing patterns, that is, who is having AI with
whom, would also be valuable to better understand the contri-
bution of this high-risk practice to the heterosexual HIV
epidemic.
Our results suggest that even low AI frequency can seriously
compromise the impact of VMB interventions. The develop-
ment of RMB and bi-compartment RVMB is essential HIV
prevention among heterosexual populations.
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